Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes

Journal of Cardiovascular Electrophysiology

Volumn 16, Issue 8, 2005, Pages 898-904

  Wu, Ying ^a   Carlsson, Leif ^c   Liu, Tengxian ^a   Kowey, Peter R ^a,b,d   Yan, Gan Xin ^a  

^a Main Line Health Heart Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d Lankenau Medical Office Building East   (United States)

Author keywords

Action potentials; Antiarrhythmia agents; Atrial fibrillation; QT interval; Torsades de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; AZD 7009; AZIMILIDE; DOFETILIDE; METHOXAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; ENDOCARDIUM; HEART MUSCLE; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE EXTRASYSTOLE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RABBIT; TORSADE DES POINTES;

EID: 26444550865     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2005.40720.x     Document Type: Article

References (27)

1. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
2. Hondeghem LM, Carlsson L, Duker G: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103:2004-2013.
3. Abrahamsson C, Carlsson L, Duker G: Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarization and early afterdepolarizations in vitro. J Cardiovasc Electrophysiol 1996;7:1074-1081.
4. Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR: Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001;103:2851-2856.
5. Medina-Ravell VA, Lankipalli RS, Yan GX, Antzelevitch C, Medina-Malpica NA, Medina-Malpica OA, Droogan C, Kowey PR: Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: Does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation 2003;107:740-746.
6. Yan GX, Lankipalli RS, Burke JF, Musco S, Kowey PR: Ventricular repolarization components on the electrocardiogram: Cellular basis and clinical significance. J Am Coll Cardiol 2003;42:401-409.
7. Hlaing T, DiMino T, Kowey PR, Yan GX: ECG repolarization waves: Their genesis and clinical implications. Ann Noninvasive Electrocardiol 2005; in press.
8. Amos GJ, Abrahamsson C, Duker G, Hondeghem L, Palmer M, Carlsson L: Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: Implications for proarrhythmic potential. Cardiovasc Res 2001;49:351-360.
9. Xu X, Yan GX, Wu Y, Liu T, Kowey PR: Electrophysiologic effects of SB-237376: A new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol 2003;41:414-421.
10. Carlsson L, Drews L, Duker G, Schiller-Linhardt G: Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther 1993;267:1076-1080.
11. Shimizu W, Antzelevitch C: Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997;96:2038-2047.
12. Goldstein RN, Khrestian C, Carlsson L, Waldo AL: AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004;15:1444-1450.
13. Linhardt G, Duker G, Carlsson L: AZD7009-A new atrial antifibrillatory compound that markedly delays atrial refractoriness and possesses low proarrhythmic activity in the anaesthetised rabbit [abstract]. Eur Heart J 2004;6:2939.
14. Persson F, Jacobson I, Carlsson L: AZD7009-A new atrial antifibrillatory compound that blocks recombinant hNav1.5 and potassium channels [abstract]. Eur Heart J 2004;6:2885.
15. Persson F, Carlsson L, Duker G, Jacobson I: Blocking characteristics of hERG, hNAv1.5 and hKvLQT1/hminK after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Electrophysiol 2005;16:329-341.
16. Yan GX, Antzelevitch C: Cellular basis for the electrocardiographic J wave. Circulation 1996;93:372-379.
17. Yan GX, Shimizu W, Antzelevitch C: The characteristics and distribution of M cells in arterially-perfused canine left ventricular wedge preparations. Circulation 1998;98:1921-1927.
18. Yan GX, Rials SJ, Wu Y, Liu T, Xu X, Marinchak RA, Kowey PR: Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am J Physiol 2001;281:H1968-H1975.
19. Yan GX, Antzelevitch C: Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998;98:1928-1936.
20. McClellan KJ, Markham A: Dofetilide: A review of its use in atrial fibrillation and atrial flutter. Drugs 1999;58:1043-1059.
21. Balati B, Varro A, Papp JG: Pharmacological modification of the dispersion of repolarization in the heart: Importance of the M cells. Cardiovasc Drugs Ther 1999;13:491-505.
22. Zygmunt AC, Eddlestone GT, Thomas GP, Nesterenko VV, Antzelevitch C: Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 2001;281:H689-H697.
23. Di Diego JM, Belardinelli L, Antzelevitch C: Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003;108:1027-1033.
24. Yan GX, Kowey PR, Lankipalli RS: Current concepts in the management of long QT syndrome. Expert Opin Ther Patents 2002;12:633-643.
25. Brooks RR, Drexler AP, Maynard AE, Al Khalidi H, Kostreva DR: Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. Proc Soc Exp Biol Med 2000;223:183-189.
26. Antzelevitch C: Tpeak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest 2001;31:555-557.
27. Joshi A, DiMino T, Vohra Y, Cui C, Yan GX: Preclinical strategies to assess QT liability and Torsadogenic potential of new drugs: The role of experimental models. J Electrocardiol 2004;37(Suppl):7-14.